KBI Biopharma
KBI Biopharma is an award winning CDMO providing fully-integrated, accelerated drug development & biomanufacturing services to pharmaceutical & biotechnology companies globally
News releases
-
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After O...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
-
KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
-
KBI Biopharma, Inc. Secures Swissmedic Regulatory Establishment License for State-of-the-Art Mammalian Cell Manufactu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory es...
-
Tim Lowery Appointed Interim CEO of KBI and Selexis
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
-
KBI Biopharma and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief...
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.
-
KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.